This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kappel, E. M.
Right arrow Articles by Stahlmann, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kappel, E. M.
Right arrow Articles by Stahlmann, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2002, p. 3320-3322, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3320-3322.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Effects of the Des-F(6)-Quinolone Garenoxacin (BMS-284756), in Comparison to Those of Ciprofloxacin and Ofloxacin, on Joint Cartilage in Immature Rats

Eva Maria Kappel,1 Mehdi Shakibaei,2 Akintunde Bello,3 and Ralf Stahlmann1*

Institute of Clinical Pharmacology and Toxicology,1 Institute of Anatomy, Benjamin Franklin Medical Center, Freie Universität Berlin, 14195 Berlin, Germany,2 Department of Clinical Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey3

Received 12 October 2001/ Returned for modification 21 March 2002/ Accepted 7 June 2002

We did not observe signs of chondrotoxicity in immature rats treated orally with garenoxacin (BMS-284756) at doses up to five times 600 mg/kg of body weight or with ciprofloxacin, whereas ofloxacin induced typical cartilage lesions. The peak plasma garenoxacin concentration was 25.5 mg/liter after administration of a dose of 600 mg/kg once daily for 5 days. Assuming that this model is predictive of human risk, BMS-284756 and ciprofloxacin should be more suitable for pediatric use than ofloxacin.

* Corresponding author. Mailing address: Institute of Clinical Pharmacology and Toxicology, Freie Universität Berlin, Garystr. 5, 14195 Berlin, Germany. Phone: 49 30 8445 1770. Fax: 49 30 8445 1763. E-mail: stahl{at}medizin.fu-berlin.de.

Antimicrobial Agents and Chemotherapy, October 2002, p. 3320-3322, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3320-3322.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Molitoris, D., Vaisanen, M.-L., Bolanos, M., Finegold, S. M. (2006). In Vitro Activities of DX-619 and Four Comparator Agents against 376 Anaerobic Bacterial Isolates.. Antimicrob. Agents Chemother. 50: 1887-1889 [Abstract] [Full Text]  
  • Ricci, V., Piddock, L. (2003). Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. J Antimicrob Chemother 52: 605-609 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»